[Clinical effect of a sustained-release theophylline formulation in moderate or severe asthmatic patients with intercrisis].
The clinical effect of the formulation of theophylline of sustained action was evaluated (Aristegui 300 mg, capsules) to the dose of 9 weight/day mg/kg (every 12 hours) in the consultation of bronchial asthma of Hospital Docente Provincial Clínico Quirúrgico de Santa Clara, in the understood period of February to September of 1997. The time of treatment was of one month and they were carried out five consultations. The sample was constituted by 30 asthmatic, moderate or severe patients. The variables were analyzed: attendance to guard's body, salbutamol use in spray and they were carried out objective mensurations from the lung function to all the patients in the different consultations. With the use of the formulation they diminished the flow expiratory pick significantly, the expiratory volume forced in one second and the flow half expiratory maximum and low incidence of adverse effects existed.
Linares Borges
A
A
Hospital Docente Provincial Clínico Quirúrgico, Santa Clara, Cuba.
Rodríguez Muñiz
J M
JM
Alemán Aguilar
H
H
Yamir Betancourt
B
B
Jiménez Hernández
L
L
Chala Tandrón
J M
JM
Martín García
L M
LM
de la Vega Elías
L
L
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D013806:Theophylline / Q000627:therapeutic use*
D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations; D013806:Theophylline
Efecto clínico de una formulación de teofilina de liberación sostenida en pacientes asmáticos moderados o severos con intercrisis.